Pragati reported on the one-dose J & J vaccine; COVID-19 replicas seen as rare

(Reuters) – The following novel is a roundup of some of the latest scientific studies on coronovirus and an attempt to treat and vaccine for the virus-causing disease COVID-19.

Johnson & Johnson vaccine through clinical trials

An experimental COVID-19 vaccine from Johnson & Johnson produced protective antibodies against novel coronoviruses in 90% of 805 volunteers for 29 days, and according to data from ongoing mid-stage studies, daytime increases to 100 % done. Researchers quickly sorted out side effects such as fever, muscle aches, and injection site pain in the New England Journal of Medicine on Wednesday. To be approved by regulators, the J&J vaccine must be reflected in a lower risk of infection and critical illness in study participants than in those who do not. Data on efficacy from a large late-stage trial on the vaccine are due in February. Experts expect the vaccine to show 80% or more efficacy, which would exceed the 50% benchmark for regulatory approval, but about 95% obtained in trials of pre-authorized vaccines from Modern Inc. and Pfizer Inc. with Biomatech SE Will cross The J&J vaccine requires only one dose, and does not have the cold storage requirements of other vaccines. “New Brunswick,” the New Jersey-based company’s chief scientific officer, Paul Stoffels, expected good results this week. (bit.ly/2LpBhHm)

COVID-19 gives some immunity, and replicas seen as rare

Survivors of COVID-19 are expected to have some immune protection against the virus for at least five months, and infections are rare in recovered patients, according to 44 cases found only in 6,614 previously infected people. Leading a large study. Workers in Britain. But when people get COVID-19 for the second time, they often have no symptoms, and so they can still carry the coronavirus to their nose and throat and pass it unknowingly, researchers said Wednesday. Wrote a report published on. Public Health England (PHE) ahead of peer review. Experts have said that people who contracted COVID-19 in the first wave of the epidemic may now be re-infected. Senior medical adviser to study leader Susan Hopkins said, “We now know that most of the people who had the virus, and developed antibodies, are protected from re-infection, but that’s not a total and we don’t know yet Not how long it lasts. ” PHE in London. “If you feel that you have already had the disease and you are safe, then you can be assured that it is not very likely that you will develop a serious infection. But there is still a risk that you can get the infection And can pass it on to others. ” (bit.ly/3ihkuBZ; reut.rs/3ieWorA)

Coronavirus targets energy engine of cells

Researchers have discovered an important line of attack used by the novel coronavirus: it targets the mitochondria of an infected cell. These small organisms not only produce the energy that drives the biochemical reactions of a cell, but they also play an important role in immune function. Dr. of the University of Southern California Pinchas Cohen said, “We knew that when viruses attack cells, bad things happen, but we don’t know why,” “Now we can say, when viruses attack cells, It damages mitochondria. ” In test tube experiments, researchers found that the virus caused “dramatic changes and loss” in genes regulating mitochondrial function, Cohen told Reuters. The implication, Cohen said, is that energy production in cells and so-called innate immunity – the body’s first line of defense against germs – is then impaired. Another implication is that having healthy mitochondria will help people combat the virus when infected. “We know that a healthy diet and healthy lifestyle promotes mitochondrial health,” Cohen said, while mitochondrial function deteriorates with age and with many chronic conditions including diabetes and heart disease. In the future, Cohen said, researchers may develop COVID-19 interventions to help improve mitochondrial health. (go.nature.com/3bFlCyc)

‘None’ combos block coronavirus, even when it mutates

According to a new study, novel antibodies to fight novel coronoviruses may be more effective than targeting small antibodies called nanobiods in conjunction with conventional antibodies or single nanobodies. The study’s leaders, Fluorine Schmidt and Paul-Albert König, said that these “multivalent” nanobodies – which have many nanobyl building blocks – are “better at neutralizing viruses” and preventing them from breaking into cells. Fused nanobodies “help each other so that the result is better than the sum of only two reactions.” According to a report published on Tuesday in the journal Science, any construct can target multiple sites on the coronovirus, making it difficult for the pathogen to develop mutations, making treatment ineffective. While researchers observed many mutations that allowed coronoviruses to “escape” the effects of a single nano, “we did not find any escape mutants that were able to replicate in the presence of nanobodies that were two different at the same time.” Target different surfaces., ”Schmidt and König said. The spin-off company of the University of Bonn, called Diosure, hopes to begin testing the nanocoll molecules combined in people later this year. (bit.ly/3nOvXKH)

Open tmsnrt.rs/3a5EyDh in an external browser for a Reuters graphic on treatments in vaccines and development.